Opinion|Videos|November 28, 2025
International LDL Thresholds
Panelists discuss how global LDL thresholds below 55 mg/dL influence care and challenge U.S. practice to evolve.
Advertisement
Episodes in this series
Panelists discuss how international guidelines—particularly European ones—have adopted aggressive low-density lipoprotein (LDL) thresholds below 55 mg/dL for high-risk patients. These approaches have driven measurable improvements in cardiovascular outcomes abroad.
The conversation examines whether the US should follow suit, balancing clinical benefit against cost, feasibility, and patient adherence.
Panelists agree that while uniform LDL standards could reduce confusion, US implementation would require payer alignment and system-wide commitment.
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
3
US Measles Outbreaks Cost Nearly $83 Million in 2026
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5